CFTC asks court to dismiss CME challenge over crypto perpetual futures

The Commodity Futures Trading Commission has asked a federal judge to dismiss CME Group’s challenge to its approval of cryptocurrency perpetual futures. The September 2 filing focuses on whether CME can show an injury that gives it standing to bring the case, rather than establishing a final judicial answer on how the contracts should be classified.

The motion was filed in the US District Court for the District of Columbia before Judge Colleen Kollar-Kotelly. As reported by CoinDesk, the agency argues that CME has not demonstrated competitive harm. A motion under Rule 12(b)(1) challenges the court’s jurisdiction; it is a request for a ruling, not a ruling itself.

How the fight started

The dispute traces to May 29, 2026, when the CFTC approved Kalshi’s cash-settled bitcoin perpetual contract, known as BTCPERP, under Regulation 40.3, and issued a policy statement making clear that any registered designated contract market could list similarly structured perpetual futures on digital commodities. Perpetual futures, or perps, have no expiration or delivery date. Traders hold leveraged long or short positions indefinitely, and periodic funding payments between longs and shorts keep the contract price anchored to the spot market.

The dispute concerns access to a type of derivative widely used in cryptocurrency markets. Its availability on a US-regulated venue does not remove the leverage, funding-cost or liquidation risks associated with the product.

CME sued on June 18. Its argument is categorical: a contract with no expiration or delivery date, where traders make periodic payments to one another, meets the Commodity Exchange Act’s definition of a swap, not a future, and therefore went through the wrong approval process. The exchange says the CFTC approved Kalshi’s product one day after submission, without public comment or formal rulemaking, and departed from earlier enforcement cases in which the agency itself had classified crypto perpetuals as swaps. Chief executive Terry Duffy has argued that products without expiration dates belong in the swap framework built by Dodd-Frank.

The regulator’s standing argument

The CFTC argues that CME and other registered exchanges can seek to offer the same type of product. Its position is that a disagreement about the regulatory label does not, by itself, demonstrate the concrete injury needed to sue.

The agency then turned CME’s own words and numbers against it. It cited public comments from CME executives saying their customers had not requested perpetual futures and that the contracts were not substitutes for the company’s institutional hedging products. And it pointed to CME’s own volume data: trading in Bitcoin, Micro Bitcoin, Ethereum and Micro Ethereum futures was higher in June and August 2026 than in May, the month the Kalshi order was issued. If the approval injured CME competitively, the CFTC argues, the injury does not show up in CME’s business.

The regulator also argues that changing the label to a swap would not necessarily eliminate the competition CME objects to. CME disputes the approval process and classification. These are opposing litigants’ arguments, and neither should be presented as a conclusion already adopted by the court.

What happens next

Reporting on the court schedule identifies October 2 as the deadline for CME’s opposition. Judge Kollar-Kotelly before the dismissal filing denied the CFTC’s request to be excused from filing the administrative record, ruling it could contain evidence relevant to CME’s alleged injury, and ordered a combined briefing schedule. CME’s opposition to the dismissal motion is due October 2, 2026. The CFTC has requested an oral hearing.

The distinction matters because a product’s legal classification affects the rules governing its listing and oversight. It is also separate from the state-versus-federal questions affecting prediction markets, discussed in TBJ’s coverage of Polymarket’s US market plans.

A dismissal could resolve this particular challenge without deciding every underlying classification question. If the motion is denied, the case could continue through further proceedings; that would not guarantee a trial or a victory for CME. The next development to watch is the response and the court’s treatment of the standing arguments.

Frequently asked questions

Why is CME suing the CFTC?

CME argues that perpetual futures, contracts with no expiration or delivery date, are legally swaps under the Commodity Exchange Act and Dodd-Frank, and that the CFTC approved Kalshi’s bitcoin perpetual through the wrong process.

What is the CFTC’s main defense?

Standing. The agency says CME cannot show concrete financial harm, that any registered exchange including CME can list the same products, and that CME’s own futures volumes rose after the Kalshi approval.

What did the CFTC approve in May?

On May 29, 2026, it approved Kalshi’s cash-settled bitcoin perpetual, BTCPERP, and issued a policy statement allowing all registered designated contract markets to list similarly structured perpetuals on digital commodities.

What is the timeline for the case?

CME’s opposition to the dismissal motion is due October 2, 2026, before Judge Colleen Kollar-Kotelly in Washington. The CFTC has requested an oral hearing.

Could the case affect markets beyond crypto?

The legal reasoning could inform future product disputes, but this motion does not establish a general approval for perpetual contracts across all asset classes.

Risk disclosure

Perpetual futures are leveraged derivative instruments that can produce losses exceeding initial margin, and funding rate mechanics can impose ongoing costs on positions. Litigation outcomes are uncertain, and the regulatory classification of perpetual contracts in the United States could change as this case proceeds.

Disclaimer: This article is for informational purposes only and does not constitute investment, legal or tax advice. Digital assets are volatile and may be subject to regulatory restrictions in your jurisdiction. Always do your own research and consult a licensed professional before making financial decisions.